DV
Dividend Vision

GENB — Generate Biomedicines, Inc. Common Stock

Generate Biomedicines, Inc. Common Stock (GENB)

Total return is -2.2% over the past 0.5 years, 15.4 points behind SPY at 13.2%.

Generate Biomedicines is a biotechnology company using machine learning and generative biology to discover and develop protein-based drug therapeutics, with a pipeline including GB-0895 for severe asthma, GB-4362 as a monoclonal antibody, and GB-5267 as a CAR-T cell therapy. The company does not currently distribute dividends. Generate Biomedicines appeals to investors seeking exposure to early-stage biotech innovation rather than current income.

GENB key facts

Asset type
Stock
Asset class
Equity
Inception date
02/26/2026
Last close
$15.64
Market cap
$1,738,290,048
Average volume
306900.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.07